Skip to content
Cancer therapy articles
- Polyketide Synthase-Mediated O-Methyloxime Formation in the Biosynthesis of the Oximidine Anticancer Agents.
Vriens E, De Ruysscher D, Weir ANM, Dekimpe S, Steurs G, Shemy A, Persoons L, Santos AR, Williams C, Daelemans D, Crump MP, Voet A, De Borggraeve W, Lescrinier E, Masschelein J. Angew Chem Int Ed Engl. 2023 Aug 21. 62(34):e202304476. doi: 10.1002/anie.202304476.
- The material properties of a bacterial-derived biomolecular condensate tune biological function in natural and synthetic systems.
Lasker K, Boeynaems S, Lam V, Scholl D, Stainton E, Briner A, Jacquemyn M, Daelemans D, Deniz A, Villa E, Holehouse AS, Gitler AD, Shapiro L.
Nat Commun. 2022 Sep 26. 13(1):5643. doi: 10.1038/s41467-022-33221-z.
- Genome-wide CRISPR screening identifies TMEM106B as a proviral host factor for SARS-CoV-2.
Baggen J, Persoons L, Vanstreels E, Jansen S, Van Looveren D, Boeckx B, Geudens V, De Man J, Jochmans D, Wauters J, Wauters E, Vanaudenaerde BM, Lambrechts D, Neyts J, Dallmeier K, Thibaut HJ, Jacquemyn M, Maes P, Daelemans D. Nat Genet. 2021 doi: 10.1038/s41588-021-00805-2
- Preclinical Assessment with Clinical Validation of Selinexor with Gemcitabine and Nab-Paclitaxel for the Treatment of Pancreatic Ductal Adenocarcinoma.
Azmi AS, Khan HY, Muqbil I, Aboukameel A, Neggers JE, Daelemans D, Mahipal A, Dyson G, Kamgar M, Al-Hallak MN, Tesfaye A, Kim S, Shidham V, M Mohammad R, Philip PA. Clin Cancer Res. 2020 Mar 15. 26(6):1338-1348. doi: 10.1158/1078-0432.CCR-19-1728.
- ATXN1 repeat expansions confer risk for amyotrophic lateral sclerosis and contribute to TDP-43 mislocalization.
Tazelaar GHP, Boeynaems S, De Decker M, van Vugt JJFA, Kool L, Goedee HS, McLaughlin RL, Sproviero W, Iacoangeli A, Moisse M, Jacquemyn M, Daelemans D, Dekker AM, van der Spek RA, Westeneng HJ, Kenna KP, Assialioui A, Da Silva N; Project MinE ALS Sequencing Consortium; Povedano M, Pardina JSM, Hardiman O, Salachas F, Millecamps S, Vourc’h P, Corcia P, Couratier P, Morrison KE, Shaw PJ, Shaw CE, Pasterkamp RJ, Landers JE, Van Den Bosch L, Robberecht W, Al-Chalabi A, van den Berg LH, Van Damme P, Veldink JH, van Es MA. Brain Commun. 2020 May 19;2(2):fcaa064. doi: 10.1093/braincomms/fcaa064.
- STK38 kinase acts as XPO1 gatekeeper regulating the nuclear export of autophagy proteins and other cargoes.
Martin AP, Jacquemyn M, Lipecka J, Chhuon C, Aushev VN, Meunier B, Singh MK, Carpi N, Piel M, Codogno P, Hergovich A, Parrini MC, Zalcman G, Guerrera IC, Daelemans D, Camonis JH. EMBO Rep. 2019 Nov 5. 20(11):e48150. doi: 10.15252/embr.201948150.
- Target identification of small molecules using large-scale CRISPR-Cas mutagenesis scanning of essential genes.
Neggers JE, Kwanten B, Dierckx T, Noguchi H, Voet A, Bral L, Minner K, Massant B, Kint N, Delforge M, Vercruysse T, Baloglu E, Senapedis W, Jacquemyn M, Daelemans D. Nat Comm. 2018.
- The second-generation exportin-1 inhibitor KPT-8602 demonstrates potent activity against acute lymphoblastic leukemia.
Vercruysse T, De Bie J, Neggers J, Jacquemyn M, Vanstreels E, Schmid-Burgk JL, Hornung V, Baloglu E, Landesman Y, Senapedis W, Shacham S, Dagklis A, Cools J, Daelemans D. Clin Cancer Res. 2016 Oct 25.
- XPO1-dependent nuclear export is a druggable vulnerability in KRAS-mutant lung cancer.
Kim J, McMillan E, Kim HS, Venkateswaran N, Makkar G, Rodriguez-Canales J, Villalobos P, Neggers JE, Mendiratta S, Wei S, Landesman Y, Senapedis W, Baloglu E, Chow CB, Frink RE, Gao B, Roth M, Minna JD, Daelemans D, Wistuba II, Posner BA, Scaglioni PP, White MA. Nature. 2016 Oct 6;538(7623):114-117
- Human exportin-1 is a target for combined therapy of HIV and AIDS related lymphoma.
Boons E, Vanstreels E, Jacquemyn M, Nogueira TC, Neggers JE, Vercruysse T, van den Oord J, Tamir S, Shacahm S, Landesman Y, Snoeck R, Pannecouque C, Andrei G, Daelemans D. EBioMedicine. 2015 2:1102-1113
- Anthranilamides with quinoline and β-carboline scaffolds: design, synthesis, and biological activity.
Beus M, Persoons L, Daelemans D, Schols D, Savijoki K, Varmanen P, Yli-Kauhaluoma J, Pavić K, Zorc B.
Mol Divers. 2022 Oct. 26(5):2595-2612. doi: 10.1007/s11030-021-10347-8.
- Antibacterial and antitumoral properties of 1,2,3-triazolo fused triterpenes and their mechanism of inhibiting the proliferation of HL-60 cells.
Wang R, Li Y, Hu H, Persoons L, Daelemans D, De Jonghe S, Luyten W, Krasniqi B, Dehaen W.
Eur J Med Chem. 2021 Nov 15. 224:113727. doi: 10.1016/j.ejmech.2021.113727.
- Discovery of ( ±)-3-(1H-pyrazol-1-yl)-6,7-dihydro-5H-[1,2,4]triazolo[3,4-b][1,3,4] thiadiazine derivatives with promising in vitro anticoronavirus and antitumoral activity.
Jilloju PC, Persoons L, Kurapati SK, Schols D, De Jonghe S, Daelemans D, Vedula RR. Mol Divers. 2022 Jun. 26(3):1357-1371. doi: 10.1007/s11030-021-10258-8.
- XPO1 inhibitors represent a novel therapeutic option in Adult T-cell Leukemia, triggering p53-mediated caspase-dependent apoptosis.
Boons E, Nogueira TC, Dierckx T, Menezes SM, Jacquemyn M, Tamir S, Landesman Y, Farré L, Bittencourt A, Kataoka K, Ogawa S, Snoeck R, Andrei G, Van Weyenbergh J, Daelemans D. Blood Cancer J. 2021 doi: 10.1038/s41408-021-00409-3.
- Synthesis, in silico ADME, molecular docking and in vitro cytotoxicity evaluation of stilbene linked 1,2,3-triazoles.
Das A, Kumar S, Persoons L, Daelemans D, Schols D, Alici H, Tahtaci H, Karki SS. Heliyon. 2021 Jan 30. 7(1):e05893. doi: 10.1016/j.heliyon.2020.e05893.
- Loss of tRNA-modifying enzyme Elp3 activates a p53-dependent antitumor checkpoint in hematopoiesis.
Rosu A, El Hachem N, Rapino F, Rouault-Pierre K, Jorssen J, Somja J, Ramery E, Thiry M, Nguyen L, Jacquemyn M, Daelemans D, Adams CM, Bonnet D, Chariot A, Close P, Bureau F, Desmet CJ. J Exp Med. 2021 Mar 1. 218(3):e20200662. doi: 10.1084/jem.20200662.
- Design, synthesis and biological evaluation of pyrazolo[3,4-d]pyrimidine-based protein kinase D inhibitors.
Gilles P, Kashyap RS, Freitas MJ, Ceusters S, Van Asch K, Janssens A, De Jonghe S, Persoons L, Cobbaut M, Daelemans D, Van Lint J, Voet ARD, De Borggraeve WM.
Eur J Med Chem. 2020 Nov 1. 11(8):1605-1610. doi: 10.1021/acsmedchemlett.0c00269.
- Synthesis of Novel Nitroxoline Analogs with Potent Cathepsin B Exopeptidase Inhibitory Activity.
Van de Walle T, Briand M, Mitrović A, Sosič I, Gobec S, Kos J, Persoons L, Daelemans D, De Jonghe S, Ubiparip Z, Desmet T, Van Hecke K, Mangelinckx S, D’hooghe M. ChemMedChem. 2020 Dec 15. 15(24):2477-2490. doi: 10.1002/cmdc.202000402.
- Preclinical Assessment with Clinical Validation of Selinexor with Gemcitabine and Nab-Paclitaxel for the Treatment of Pancreatic Ductal Adenocarcinoma.
Azmi AS, Khan HY, Muqbil I, Aboukameel A, Neggers JE, Daelemans D, Mahipal A, Dyson G, Kamgar M, Al-Hallak MN, Tesfaye A, Kim S, Shidham V, M Mohammad R, Philip PA. Clin Cancer Res. 2020 Mar 15. 26(6):1338-1348. doi: 10.1158/1078-0432.CCR-19-1728.
- Design and Synthesis of New 6-Nitro and 6-Amino-3,3a,4,5-Tetrahydro-2H-Benzo[g]indazole Derivatives: Antiproliferative and Antibacterial Activity.
Cuartas V, Crespo MDP, Priego EM, Persoons L, Daelemans D, Camarasa MJ, Insuasty B, Pérez-Pérez MJ.
Molecules. 2019 Nov 21. 24(23):4236. doi: 10.3390/molecules24234236.
- Down-regulation of AR splice variants through XPO1 suppression contributes to the inhibition of prostate cancer progression.
Aboukameel A, Muqbil I, Baloglu E, Senapedis W, Landesman Y, Argueta C, Kauffman M, Chang H, Kashyap T, Shacham S, Neggers JE, Daelemans D, Heath EI, Azmi AS. Oncotarget. 2018 Oct 19. 9(82):35327-35342. doi: 10.18632/oncotarget.26239.
- Targeting the XPO1-dependent nuclear export of E2F7 reverses anthracycline resistance in head and neck squamous cell carcinomas.
Saenz-Ponce N, Pillay R, de Long LM, Kashyap T, Argueta C, Landesman Y, Hazar-Rethinam M, Boros S, Panizza B, Jacquemyn M, Daelemans D, Gannon OM, Saunders NA.
Sci Transl Med. 2018 Jun 27. 10(447):eaar7223. doi: 10.1126/scitranslmed.aar7223..
- Synthesis and Biological Evaluation of Pyrrolo[2,1-f][1,2,4]triazine C-Nucleosides with a Ribose, 2′-Deoxyribose, and 2′,3′-Dideoxyribose Sugar Moiety.
Li Q, Lescrinier E, Groaz E, Persoons L, Daelemans D, Herdewijn P, De Jonghe S. ChemMedChem. 2018 Jan 8. 13(1):97-104. doi: 10.1002/cmdc.201700657.
- The second-generation exportin-1 inhibitor KPT-8602 demonstrates potent activity against acute lymphoblastic leukemia.
Vercruysse T, De Bie J, Neggers J, Jacquemyn M, Vanstreels E, Schmid-Burgk JL, Hornung V, Baloglu E, Landesman Y, Senapedis W, Shacham S, Dagklis A, Cools J, Daelemans D. Clin Cancer Res. 2016 Oct 25.
- XPO1-dependent nuclear export is a druggable vulnerability in KRAS-mutant lung cancer.
Kim J, McMillan E, Kim HS, Venkateswaran N, Makkar G, Rodriguez-Canales J, Villalobos P, Neggers JE, Mendiratta S, Wei S, Landesman Y, Senapedis W, Baloglu E, Chow CB, Frink RE, Gao B, Roth M, Minna JD, Daelemans D, Wistuba II, Posner BA, Scaglioni PP, White MA. Nature. 2016 Oct 6;538(7623):114-117
- Human exportin-1 is a target for combined therapy of HIV and AIDS related lymphoma.
Boons E, Vanstreels E, Jacquemyn M, Nogueira TC, Neggers JE, Vercruysse T, van den Oord J, Tamir S, Shacahm S, Landesman Y, Snoeck R, Pannecouque C, Andrei G, Daelemans D. EBioMedicine. 2015 2:1102-1113
- Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia.
Lapalombella R, Sun Q, Williams K, Tangeman L, Jha S, Zhong Y, Goettl V, Mahoney E, Berglund C, Gupta S, Farmer A, Mani R, Johnson AJ, Lucas D, Mo X, Daelemans D, Sandanayaka V, Shechter S, McCauley D, Shacham S, Kauffman M, Chook YM, Byrd JC. Blood. 2012 Nov 29;120(23):4621-34.
